Bureau of Health Care Quality and Compliance

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:	(X2) MULTIPLE CONSTRUCTION	(X3) DATE SURVEY COMPLETED
	NVS6117OPF	A. BUILDING _____ B. WING _____	05/10/2011

NAME OF PROVIDER OR SUPPLIER	STREET ADDRESS, CITY, STATE, ZIP CODE
COMPREHENSIVE CANCER CENTERS OF NEVADA	3196 S MARYLAND PKWY #400 NORTH LAS VEGAS, NV 89031

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETE DATE
O 000	Initial Comments This Statement of Deficiencies was generated as a result of a State Permitting Inspection conducted in your facility on 5/10/11, in accordance with Nevada Administrative Code, Chapter 449, Outpatient Facility. The findings and conclusions of any investigation by the Health Division shall not be construed as prohibiting any criminal or civil investigations, actions or other claims for relief that may be available to any party under applicable federal, state or local laws. The following regulatory deficiencies were identified:	O 000		
O 080	Use Of Vials Section 30. Use of single dose vials: Each program for the prevention and control of infections and communicable diseases must include policies and procedures for single-dose vials which provide that a single-dose vial may be accessed only by using an aseptic technique. The policies and procedures must provide that: (a) Each injection of a medication from a single-dose vial must be prepared in a clean, designated area where contamination by blood or bodily fluid is unlikely to occur; (b) The medication in a single-dose vial must not be used for more than one patient; (c) A single-dose vial, including any remaining medication in the vial after its use, must be discarded; and (d) Any remaining medication in a single-dose vial after its use must not be combined with any other	O 080		

If deficiencies are cited, an approved plan of correction must be returned within 10 days after receipt of this statement of deficiencies.

TITLE (X6) DATE

LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER REPRESENTATIVE'S SIGNATURE

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:	(X2) MULTIPLE CONSTRUCTION	(X3) DATE SURVEY COMPLETED
	NVS6117OPF	A. BUILDING _____ B. WING _____	05/10/2011

NAME OF PROVIDER OR SUPPLIER	STREET ADDRESS, CITY, STATE, ZIP CODE
COMPREHENSIVE CANCER CENTERS OF NEVADA	3196 S MARYLAND PKWY #400 NORTH LAS VEGAS, NV 89031

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETE DATE
O 080	Continued From page 1 medication or otherwise used for any other patients. Use of multidose vials: Each program for the prevention and control of infections and communicable diseases must include policies and procedures for multidose vials which provide that a multidose vial may be accessed only by using an aseptic technique. The policies and procedures must provide that: (a) The cap of a multidose vial must be cleaned with an alcohol-based wipe before the vial is accessed; (b) A new sterile needle and new sterile syringe must be used each time to access a multidose vial; (c) Upon first access of a multidose vial, the person who accessed the vial shall date and initial the vial; (d) Each injection of a medication from a multidose vial must be prepared in a clean, designated area where contamination by blood or bodily fluid is unlikely to occur; (e) A needle must not be left inserted in the cap of a multidose vial after its use; and (f) A multidose vial must be discarded when the medication in the vial has expired or 28 days after the vial was initially accessed. This STANDARD is not met as evidenced by: Based on observation, interview and document review, the facility failed to date and initial 18 opened vials of medication. 1. On 5/10/11 at 9:50 AM, Methotrexate, Ketamine, Mesna and Ondansetron were observed in the medication cupboard in the pharmacy to be opened. There was no evidence	O 080		

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:	(X2) MULTIPLE CONSTRUCTION	(X3) DATE SURVEY COMPLETED
	NVS6117OPF	A. BUILDING _____ B. WING _____	05/10/2011

NAME OF PROVIDER OR SUPPLIER	STREET ADDRESS, CITY, STATE, ZIP CODE
COMPREHENSIVE CANCER CENTERS OF NEVADA	3196 S MARYLAND PKWY #400 NORTH LAS VEGAS, NV 89031

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETE DATE
O 080	Continued From page 2 the opened vials of medication had been dated and initialed. 2. On 5/10/11 at 10:05 AM, Pegaspargase, Neupogen (2 vials), Lorazepam (2 vials), Doxorubicin, Rituxan, Avastin, Vincristine (2 vials), vinblastine, cyclophosphamide, cytarabine and topotecan were observed in the refrigerator in the pharmacy opened with no date and initials. 3. On 5/10/11 at 9:50 AM, the pharmacy technician was interviewed. The employee explained the vials were to be used the same day. The employee explained the tops of the vials had come off when he pulled them out of the boxes and the medication and not been used. Severity: 2 Scope: 3	O 080		